246 related articles for article (PubMed ID: 35386712)
1. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
2. Increased Efficiency for Biallelic Mutations of the
Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
4. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
7. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
9. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
10. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
Au TY; Arudkumar J; Assavarittirong C; Benjamin S
Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
[TBL] [Abstract][Full Text] [Related]
11.
Xu M
Cell Biosci; 2020; 10():48. PubMed ID: 32257106
[TBL] [Abstract][Full Text] [Related]
12. Efficient biallelic knock-in in mouse embryonic stem cells by in vivo-linearization of donor and transient inhibition of DNA polymerase θ/DNA-PK.
Arai D; Nakao Y
Sci Rep; 2021 Sep; 11(1):18132. PubMed ID: 34518609
[TBL] [Abstract][Full Text] [Related]
13. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
14. Targeted integration in human cells through single crossover mediated by ZFN or CRISPR/Cas9.
Liu X; Wang M; Qin Y; Shi X; Cong P; Chen Y; He Z
BMC Biotechnol; 2018 Oct; 18(1):66. PubMed ID: 30340581
[TBL] [Abstract][Full Text] [Related]
15. A high-efficiency and versatile CRISPR/Cas9-mediated HDR-based biallelic editing system.
Li X; Sun B; Qian H; Ma J; Paolino M; Zhang Z
J Zhejiang Univ Sci B; 2022 Feb; 23(2):141-152. PubMed ID: 35187887
[TBL] [Abstract][Full Text] [Related]
16. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
Takácová M; Nogová P; Hábeková M; Staneková D
Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
[TBL] [Abstract][Full Text] [Related]
18. Efficient SSA-mediated precise genome editing using CRISPR/Cas9.
Li X; Bai Y; Cheng X; Kalds PGT; Sun B; Wu Y; Lv H; Xu K; Zhang Z
FEBS J; 2018 Sep; 285(18):3362-3375. PubMed ID: 30085411
[TBL] [Abstract][Full Text] [Related]
19. Distribution of the mutated delta 32 allele of the CCR5 gene in a Sicilian population.
Sidoti A; D'Angelo R; Rinaldi C; De Luca G; Pino F; Salpietro C; Giunta DE; Saltalamacchia F; Amato A
Int J Immunogenet; 2005 Jun; 32(3):193-8. PubMed ID: 15932625
[TBL] [Abstract][Full Text] [Related]
20. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus.
Kang H; Minder P; Park MA; Mesquitta WT; Torbett BE; Slukvin II
Mol Ther Nucleic Acids; 2015 Dec; 4():e268. PubMed ID: 26670276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]